Drug intelligence / Profile preview

carboplatin + pemetrexed + sotorasib

Development stage: Unknown
Lead developer: Amgen
Modality: Small Molecules
Administration: Oral, Intravenous

Overview

Carboplatin + pemetrexed + sotorasib is a combination therapy being investigated for the treatment of KRAS G12C-mutated advanced non-small cell lung cancer (NSCLC). This regimen combines traditional platinum-based chemotherapy (carboplatin and pemetrexed) with targeted therapy (sotorasib). Sotorasib is an irreversible and selective inhibitor of mutated KRAS G12C that forms a covalent bond with the cysteine in the G12C transversion, locking the mutant protein in an inactive form without affecting wild-type KRAS. The combination aims to improve anti-tumor activity and overcome therapeutic resistance in KRAS G12C-mutated NSCLC.

Brand names: Lumakras
Other names: sotorasib plus carboplatin and pemetrexed

Targets

KRASG12C (Kirsten rat sarcoma viral oncogene homolog G12C)

Beyond the preview

Go deeper on carboplatin + pemetrexed + sotorasib.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on carboplatin + pemetrexed + sotorasib.

Explore the full profile